{"id":27090,"date":"2025-01-17T15:25:23","date_gmt":"2025-01-17T22:25:23","guid":{"rendered":"https:\/\/ameripharmaspecialty.com\/?p=27090"},"modified":"2025-01-17T15:25:25","modified_gmt":"2025-01-17T22:25:25","slug":"ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights","status":"publish","type":"post","link":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/","title":{"rendered":"IgIV para la aplasia adquirida de gl\u00f3bulos rojos: beneficios clave y perspectivas terap\u00e9uticas"},"content":{"rendered":"<p><a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/acquired-pure-red-cell-aplasia\">Aplasia adquirida de gl\u00f3bulos rojos<\/a> La aplasia pura de gl\u00f3bulos rojos adquirida (APE) es un subtipo de aplasia pura de gl\u00f3bulos rojos (APRC), un trastorno sangu\u00edneo poco com\u00fan en el que la m\u00e9dula \u00f3sea no produce suficientes gl\u00f3bulos rojos (GR). Cuando una persona con este trastorno no tiene suficientes gl\u00f3bulos rojos en el cuerpo, se siente fatigada, sin aliento, let\u00e1rgica o d\u00e9bil debido a una enfermedad grave. <a href=\"https:\/\/www.mayoclinic.org\/diseases-conditions\/anemia\/symptoms-causes\/syc-20351360\">anemia<\/a>.&nbsp;&nbsp;<\/p>\n\n\n\n<div  id=\"call-to-action-15d13fdf434d9c955dea1554a3e68a7e\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\t\u00bfPuede ayudar la IgIV?\u00a0\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<span class=\"cta__sub__heading\">\n\t\t\t\t\t\t\tInformaci\u00f3n gratuita sobre el tratamiento con IgIV\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<p>La terapia con inmunoglobulina intravenosa (IVIG) ha <a href=\"https:\/\/academic.oup.com\/cid\/article-abstract\/56\/7\/968\/359513?redirectedFrom=fulltext\">surgi\u00f3 como una opci\u00f3n de tratamiento eficaz<\/a> para la aplasia de gl\u00f3bulos rojos adquirida (aPRCA), especialmente en los casos en que esta afecci\u00f3n es desencadenada o causada por trastornos autoinmunes o infecciones virales.&nbsp;<\/p>\n\n\n\n<p>Analicemos con m\u00e1s detalle los conceptos b\u00e1sicos de la aplasia adquirida de gl\u00f3bulos rojos, c\u00f3mo se produce y c\u00f3mo <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig\/\">Terapia con IgIV<\/a> Puede ayudar a los pacientes con este raro trastorno de la m\u00e9dula \u00f3sea.&nbsp;<\/p>\n\n\n\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_82_2 counter-hierarchy ez-toc-counter ez-toc-custom ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Alternar tabla de contenido\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Palanca<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewbox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewbox=\"0 0 24 24\" version=\"1.2\" baseprofile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#What_Is_Acquired_Red_Cell_Aplasia\" >\u00bfQu\u00e9 es la aplasia adquirida de gl\u00f3bulos rojos?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#What_Causes_Acquired_Red_Cell_Aplasia\" >\u00bfQu\u00e9 causa la aplasia adquirida de gl\u00f3bulos rojos?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#How_IVIG_Therapy_Can_Treat_Acquired_Red_Cell_Aplasia\" >C\u00f3mo la terapia con IgIV puede tratar la aplasia adquirida de gl\u00f3bulos rojos<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#What_Is_the_Standard_Dose_of_IVIG_for_Acquired_Red_Cell_Aplasia\" >\u00bfCu\u00e1l es la dosis est\u00e1ndar de IgIV para la aplasia de gl\u00f3bulos rojos adquirida?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#How_Does_IVIG_Benefit_Patients_with_Acquired_Red_Cell_Aplasia\" >\u00bfC\u00f3mo beneficia la IgIV a los pacientes con aplasia de gl\u00f3bulos rojos adquirida?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#What_To_Expect_During_IVIG_Treatment\" >Qu\u00e9 esperar durante el tratamiento con IgIV<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#Conclusion\" >Conclusi\u00f3n<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\" id=\"h-what-is-acquired-red-cell-aplasia\"><span class=\"ez-toc-section\" id=\"What_Is_Acquired_Red_Cell_Aplasia\"><\/span><strong>\u00bfQu\u00e9 es la aplasia adquirida de gl\u00f3bulos rojos?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La aplasia pura de gl\u00f3bulos rojos adquirida es una enfermedad sangu\u00ednea poco com\u00fan que se caracteriza por una anemia grave causada por una disminuci\u00f3n significativa de la producci\u00f3n de gl\u00f3bulos rojos (tambi\u00e9n llamados eritrocitos) en la m\u00e9dula \u00f3sea. Esta disminuci\u00f3n dr\u00e1stica puede deberse a una insuficiencia de la eritropoyesis.&nbsp;<\/p>\n\n\n\n<p>La eritropoyesis es el proceso de producci\u00f3n de gl\u00f3bulos rojos en la m\u00e9dula \u00f3sea. Cualquier problema con este proceso puede reducir la cantidad de gl\u00f3bulos rojos inmaduros disponibles (tambi\u00e9n llamados... <a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/31194329\/\">reticulocitos<\/a>). Estas c\u00e9lulas se liberan desde la m\u00e9dula \u00f3sea al torrente sangu\u00edneo y se convierten en gl\u00f3bulos rojos maduros.&nbsp;<\/p>\n\n\n\n<p>Un recuento bajo de gl\u00f3bulos rojos puede provocar anemia grave, que puede causar s\u00edntomas como mareos, fatiga, dificultad para respirar, ritmo card\u00edaco acelerado, debilidad o piel p\u00e1lida.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-causes-acquired-red-cell-aplasia\"><span class=\"ez-toc-section\" id=\"What_Causes_Acquired_Red_Cell_Aplasia\"><\/span><strong>\u00bfQu\u00e9 causa la aplasia adquirida de gl\u00f3bulos rojos?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>A diferencia de <a href=\"https:\/\/www.aamds.org\/diseases\/related\/pure-red-cell-aplasia-prca#:~:text=Inherited%20or%20Congenital%20Pure%20Red,cases%20have%20been%20reported%20worldwide.\">aplasia de gl\u00f3bulos rojos hereditaria o cong\u00e9nita<\/a>La aplasia eritrocitaria pura adquirida, causada por una mutaci\u00f3n (un error) en ciertos genes, se debe a diversos factores externos. Seg\u00fan los factores que intervienen en su aparici\u00f3n, se clasifica en aplasia eritrocitaria adquirida primaria y secundaria:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Aplasia primaria adquirida de gl\u00f3bulos rojos: <\/strong>Primario: la aPRCA es una enfermedad autoinmune, lo que significa que el sistema inmunitario produce prote\u00ednas, llamadas autoanticuerpos, que luego atacan a las c\u00e9lulas madre formadoras de sangre en la m\u00e9dula \u00f3sea.\u00a0<\/li>\n\n\n\n<li><strong>Aplasia de gl\u00f3bulos rojos adquirida secundaria: <\/strong>Se cree que la aPRCA secundaria es causada por otras afecciones m\u00e9dicas, como tumores s\u00f3lidos (timoma), enfermedades autoinmunes (como lupus eritematoso sist\u00e9mico, leucemia linfoc\u00edtica cr\u00f3nica o artritis reumatoide), infecciones (principalmente parvovirus B19) o ciertos medicamentos.\u00a0<\/li>\n<\/ul>\n\n\n\n<p>Se cree que la aPRCA primaria o secundaria se puede tratar atacando la causa subyacente (es decir, enfermedad autoinmune, c\u00e1ncer o infecciones).&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-ivig-therapy-can-treat-acquired-red-cell-aplasia\"><span class=\"ez-toc-section\" id=\"How_IVIG_Therapy_Can_Treat_Acquired_Red_Cell_Aplasia\"><\/span><strong>C\u00f3mo la terapia con IgIV puede tratar la aplasia adquirida de gl\u00f3bulos rojos<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"alignright size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"420\" height=\"280\" src=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient.jpg\" alt=\"Man in bed at home receiving IVIG therapy for acquired red cell aplasia\" class=\"wp-image-27093\" srcset=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient.jpg 420w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient-300x200.jpg 300w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient-330x220.jpg 330w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient-86x57.jpg 86w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient-167x111.jpg 167w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient-280x187.jpg 280w, https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-patient-370x247.jpg 370w\" sizes=\"auto, (max-width: 420px) 100vw, 420px\" \/><\/figure>\n<\/div>\n\n\n<p>En general, la terapia con IgIV proporciona un beneficio esencial. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/immunoglobulins-ig\/\">anticuerpos<\/a> que ayudan a regular el sistema inmunol\u00f3gico, ya sea debilitando la respuesta inmune hiperactiva o aumentando la actividad del sistema inmunol\u00f3gico cuando sea necesario.&nbsp;<\/p>\n\n\n\n<p>Para los pacientes con aPRCA, la terapia con IgIV puede ayudar a modular la respuesta inmunitaria al:&nbsp;<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Regulaci\u00f3n de las c\u00e9lulas inmunes:<\/strong> En el caso de aPRCA causada por enfermedades autoinmunes, la terapia con IgIV disminuye la actividad de ciertas c\u00e9lulas inmunes, particularmente <a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-terms\/def\/t-cell\">c\u00e9lulas T<\/a>, que podr\u00eda estar implicada en el ataque a los precursores de gl\u00f3bulos rojos. Por lo tanto, se puede prevenir un mayor da\u00f1o a la m\u00e9dula \u00f3sea con la ayuda del tratamiento con IgIV.\u00a0\u00a0<\/li>\n\n\n\n<li><strong>Bloqueo de autoanticuerpos: <\/strong>En los trastornos autoinmunes, el sistema inmunitario produce autoanticuerpos que atacan por error a los gl\u00f3bulos rojos o a sus precursores, lo que provoca un recuento bajo de gl\u00f3bulos rojos. La IgIV bloquea estos autoanticuerpos uni\u00e9ndose a ellos e impidiendo que destruyan los gl\u00f3bulos rojos en el torrente sangu\u00edneo o sus precursores en la m\u00e9dula \u00f3sea.\u00a0<\/li>\n<\/ul>\n\n\n\n<div  id=\"call-to-action-3b89aa05050cdfab5bfbb0936c67f5eb\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tObtenga asistencia para el copago de IgIV\u00a0\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"#form\">Empezar<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Fortalecimiento de la respuesta inmunitaria contra las infecciones:<\/strong> En algunos casos, <a href=\"https:\/\/ashpublications.org\/blood\/article\/128\/21\/2504\/35728\/Pure-red-cell-aplasia\">La aplasia adquirida de gl\u00f3bulos rojos es causada por una infecci\u00f3n viral.<\/a>, como el parvovirus humano B19. El virus infecta las c\u00e9lulas progenitoras eritroides humanas, que son las c\u00e9lulas implicadas en el proceso de producci\u00f3n de gl\u00f3bulos rojos. La IgIV ayuda a reforzar la respuesta inmunitaria en personas con sistemas inmunitarios debilitados al proporcionar anticuerpos esenciales. Estos anticuerpos atacan y destruyen el virus, impidiendo as\u00ed que ataque a las c\u00e9lulas progenitoras eritroides. De hecho, una <a href=\"https:\/\/academic.oup.com\/cid\/article-abstract\/56\/7\/968\/359513?redirectedFrom=fulltext\">estudio de investigaci\u00f3n<\/a> Un estudio con 133 pacientes con PRCA por VPH-B19 mostr\u00f3 que el 93% de los pacientes experiment\u00f3 una mejora en sus niveles de hemoglobina tras el primer ciclo de IgIV. Este estudio tambi\u00e9n sugiere que la terapia con IgIV es eficaz en el tratamiento de la PRCA por VPH-B19 en pacientes inmunodeprimidos.\u00a0<\/li>\n\n\n\n<li><strong>Ejerciendo efectos antiinflamatorios:<\/strong> Durante una respuesta inmunitaria hiperactiva, puede producirse inflamaci\u00f3n en la m\u00e9dula \u00f3sea, lo que puede afectar la producci\u00f3n de gl\u00f3bulos rojos. Dado que la IgIV tiene propiedades antiinflamatorias, ayuda a reducir la inflamaci\u00f3n en la m\u00e9dula \u00f3sea, creando un entorno m\u00e1s favorable para la producci\u00f3n de gl\u00f3bulos rojos.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-the-standard-dose-of-ivig-for-acquired-red-cell-aplasia\"><span class=\"ez-toc-section\" id=\"What_Is_the_Standard_Dose_of_IVIG_for_Acquired_Red_Cell_Aplasia\"><\/span><strong>\u00bfCu\u00e1l es la dosis est\u00e1ndar de IgIV para la aplasia de gl\u00f3bulos rojos adquirida?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La dosis de IgIV puede variar considerablemente entre personas. Generalmente, se basa en el tipo de afecci\u00f3n subyacente que causa la aPRCA. Por ejemplo, varios estudios de caso sugirieron que... <a href=\"https:\/\/ashpublications.org\/blood\/article\/128\/21\/2504\/35728\/Pure-red-cell-aplasia\">dosis alta de IgIV (2 g\/kg), generalmente dividida en 5 d\u00edas (400 mg\/kg\/d\u00eda)<\/a>, es m\u00e1s eficaz en el tratamiento de la PRCA asociada con la infecci\u00f3n por parvovirus B19 en pacientes inmunodeprimidos.&nbsp;<\/p>\n\n\n\n<p>Sin embargo, para las personas que experimentan una reca\u00edda (anemia grave) despu\u00e9s de 3 meses, se recomienda una dosis de mantenimiento de 1 g\/kg de IgIV durante 2 d\u00edas.&nbsp;<\/p>\n\n\n\n<p>Es importante consultar a su proveedor de atenci\u00f3n m\u00e9dica para comprender su per\u00edodo de tratamiento con IgIV y la frecuencia de las dosis.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-how-does-ivig-benefit-patients-with-acquired-red-cell-aplasia\"><span class=\"ez-toc-section\" id=\"How_Does_IVIG_Benefit_Patients_with_Acquired_Red_Cell_Aplasia\"><\/span><strong>\u00bfC\u00f3mo beneficia la IgIV a los pacientes con aplasia de gl\u00f3bulos rojos adquirida?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La terapia con IgIV ofrece varios beneficios potenciales para aquellos con aplasia de gl\u00f3bulos rojos adquirida:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>La IgIV modula r\u00e1pidamente el sistema inmunol\u00f3gico, lo que la convierte en una opci\u00f3n valiosa para los pacientes que necesitan tratamiento inmediato.\u00a0<\/li>\n\n\n\n<li>La IgIV es un tratamiento no invasivo que tiene menos riesgos en comparaci\u00f3n con el trasplante de m\u00e9dula \u00f3sea.\u00a0<\/li>\n\n\n\n<li>La IgIV es una terapia vers\u00e1til gracias a sus m\u00faltiples mecanismos de acci\u00f3n. En pacientes con aPRCA, puede tratar tanto las causas autoinmunes como las infecciosas asociadas con esta afecci\u00f3n.<\/li>\n<\/ul>\n\n\n\n<div  id=\"call-to-action-721115c1d42fad2f8cdbc7b0c0ed249f\" style=\"\" class=\"ct_call_to_action\">\n\t<div class=\"container\">\n\t\t<div class=\"block-wrap cta\">\n\t\t\t<div class=\"block-column\">\n\t\t\t\t<div class=\"cta_headings\">\n\t\t\t\t\t\t\t\t\t\t\t<h4 class=\"cta__heading\">\n\t\t\t\t\t\t\tConsulte a un especialista en IgIV\t\t\t\t\t\t<\/h4>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<span class=\"cta_btn\">\n\t\t\t\t\t\t<a href=\"tel:8777780318\">(877) 778-0318<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/span>\n\t\t\t\t\t\t\t<\/div>\n\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-to-expect-during-ivig-treatment\"><span class=\"ez-toc-section\" id=\"What_To_Expect_During_IVIG_Treatment\"><\/span><strong>Qu\u00e9 esperar durante el tratamiento con IgIV<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>El tratamiento con IgIV se administra mediante una infusi\u00f3n lenta en las venas (v\u00eda intravenosa o IV). Mientras recibe el tratamiento con IgIV, es posible que experimente algunos s\u00edntomas leves. <a href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/understanding-the-common-side-effects-of-ivig-treatment\/\">efectos secundarios<\/a> Como dolor de cabeza, n\u00e1useas, fiebre baja o dolor muscular o articular. Dependiendo de su situaci\u00f3n, podr\u00eda recibir IgIV en un centro de atenci\u00f3n m\u00e9dica (por ejemplo, un centro de infusi\u00f3n o el consultorio de un profesional de la salud) o en su domicilio.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-conclusion\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusi\u00f3n<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>La terapia con IgIV parece ser una opci\u00f3n eficaz para tratar la aPRCA, especialmente en casos donde la causa es una infecci\u00f3n viral o una enfermedad autoinmune. Sin embargo, la terapia con IgIV puede causar algunos efectos secundarios leves que deben considerarse antes de iniciar el tratamiento. Su profesional de la salud puede analizar los riesgos y beneficios del uso de IgIV para tratar la aPRCA seg\u00fan su situaci\u00f3n cl\u00ednica.<\/p>","protected":false},"excerpt":{"rendered":"<p>La aplasia de gl\u00f3bulos rojos adquirida o aplasia de gl\u00f3bulos rojos pura adquirida es un subtipo de aplasia de gl\u00f3bulos rojos pura (PRCA), un trastorno sangu\u00edneo poco com\u00fan en el que la m\u00e9dula \u00f3sea no produce suficientes gl\u00f3bulos rojos (RBC).<\/p>","protected":false},"author":26,"featured_media":27091,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":true,"om_disable_all_campaigns":false,"_uag_custom_page_level_css":"","footnotes":""},"categories":[7],"tags":[32],"class_list":["post-27090","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ivig","tag-dr-robert-hakim"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights - AmeriPharma\u00ae Specialty Care<\/title>\n<meta name=\"description\" content=\"This article covers the basics of acquired red cell aplasia, how it occurs, and how IVIG therapy can help with this rare disorder.\u00a0\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights - AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"og:description\" content=\"This article covers the basics of acquired red cell aplasia, how it occurs, and how IVIG therapy can help with this rare disorder.\u00a0\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/\" \/>\n<meta property=\"og:site_name\" content=\"AmeriPharma\u00ae Specialty Care\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ameripharma\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-17T22:25:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-17T22:25:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Dr. Robert Hakim, PharmD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dr. Robert Hakim, PharmD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/\"},\"author\":{\"name\":\"Dr. Robert Hakim, PharmD\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\"},\"headline\":\"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights\",\"datePublished\":\"2025-01-17T22:25:23+00:00\",\"dateModified\":\"2025-01-17T22:25:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/\"},\"wordCount\":1073,\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/ivig-arm.jpg\",\"keywords\":[\"Dr. Robert Hakim\"],\"articleSection\":[\"IVIG\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/\",\"name\":\"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights - AmeriPharma\u00ae Specialty Care\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/ivig-arm.jpg\",\"datePublished\":\"2025-01-17T22:25:23+00:00\",\"dateModified\":\"2025-01-17T22:25:25+00:00\",\"description\":\"This article covers the basics of acquired red cell aplasia, how it occurs, and how IVIG therapy can help with this rare disorder.\u00a0\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/ivig-arm.jpg\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/ivig-arm.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Closeup of the arm of a woman receiving IVIG therapy\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/vi\\\/ivig\\\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#website\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"name\":\"AmeriPharma\u00ae Specialty Care\",\"description\":\"Specialty Care by AmeriPharma\",\"publisher\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#organization\",\"name\":\"Ameripharma Specialty Care\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"contentUrl\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/specialty-care-logo-large-square.png\",\"width\":400,\"height\":400,\"caption\":\"Ameripharma Specialty Care\"},\"image\":{\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ameripharma\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/#\\\/schema\\\/person\\\/234280933b6e0dcaf47c0c1f40a59759\",\"name\":\"Dr. Robert Hakim, PharmD\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g\",\"caption\":\"Dr. Robert Hakim, PharmD\"},\"description\":\"Dr. Robert Chad Hakim, PharmD, was born and raised in Northridge, CA. He received his pharmacy degree from the University of Wisconsin-Madison School of Pharmacy. The most rewarding part of his job is taking initiative to advance clinical programs that maximize impact on patient care. He has a board certification in critical care (BCCCP), and his areas of expertise are critical care, drug information, general medicine, and cardiology. In his free time, he enjoys traveling.\u00a0\",\"url\":\"https:\\\/\\\/ameripharmaspecialty.com\\\/es\\\/author\\\/robert-hakim\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IgIV para la aplasia adquirida de gl\u00f3bulos rojos: beneficios clave y perspectivas terap\u00e9uticas - AmeriPharma\u00ae Specialty Care","description":"Este art\u00edculo cubre los conceptos b\u00e1sicos de la aplasia de gl\u00f3bulos rojos adquirida, c\u00f3mo se produce y c\u00f3mo la terapia con IgIV puede ayudar con este trastorno poco com\u00fan.\u00a0","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/","og_locale":"es_MX","og_type":"article","og_title":"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights - AmeriPharma\u00ae Specialty Care","og_description":"This article covers the basics of acquired red cell aplasia, how it occurs, and how IVIG therapy can help with this rare disorder.\u00a0","og_url":"https:\/\/ameripharmaspecialty.com\/es\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/","og_site_name":"AmeriPharma\u00ae Specialty Care","article_publisher":"https:\/\/www.facebook.com\/ameripharma\/","article_published_time":"2025-01-17T22:25:23+00:00","article_modified_time":"2025-01-17T22:25:25+00:00","og_image":[{"width":1280,"height":853,"url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg","type":"image\/jpeg"}],"author":"Dr. Robert Hakim, PharmD","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Dr. Robert Hakim, PharmD","Est. reading time":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#article","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/"},"author":{"name":"Dr. Robert Hakim, PharmD","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759"},"headline":"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights","datePublished":"2025-01-17T22:25:23+00:00","dateModified":"2025-01-17T22:25:25+00:00","mainEntityOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/"},"wordCount":1073,"publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg","keywords":["Dr. Robert Hakim"],"articleSection":["IVIG"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/","url":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/","name":"IgIV para la aplasia adquirida de gl\u00f3bulos rojos: beneficios clave y perspectivas terap\u00e9uticas - AmeriPharma\u00ae Specialty Care","isPartOf":{"@id":"https:\/\/ameripharmaspecialty.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#primaryimage"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#primaryimage"},"thumbnailUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg","datePublished":"2025-01-17T22:25:23+00:00","dateModified":"2025-01-17T22:25:25+00:00","description":"Este art\u00edculo cubre los conceptos b\u00e1sicos de la aplasia de gl\u00f3bulos rojos adquirida, c\u00f3mo se produce y c\u00f3mo la terapia con IgIV puede ayudar con este trastorno poco com\u00fan.\u00a0","breadcrumb":{"@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#primaryimage","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg","width":1280,"height":853,"caption":"Closeup of the arm of a woman receiving IVIG therapy"},{"@type":"BreadcrumbList","@id":"https:\/\/ameripharmaspecialty.com\/vi\/ivig\/ivig-for-acquired-red-cell-aplasia-key-benefits-and-treatment-insights\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ameripharmaspecialty.com\/"},{"@type":"ListItem","position":2,"name":"IVIG for Acquired Red Cell Aplasia: Key Benefits and Treatment Insights"}]},{"@type":"WebSite","@id":"https:\/\/ameripharmaspecialty.com\/#website","url":"https:\/\/ameripharmaspecialty.com\/","name":"Cuidado especializado AmeriPharma\u00ae","description":"Atenci\u00f3n especializada por AmeriPharma","publisher":{"@id":"https:\/\/ameripharmaspecialty.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ameripharmaspecialty.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/ameripharmaspecialty.com\/#organization","name":"Atenci\u00f3n especializada de Ameripharma","url":"https:\/\/ameripharmaspecialty.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/","url":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","contentUrl":"https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2024\/07\/specialty-care-logo-large-square.png","width":400,"height":400,"caption":"Ameripharma Specialty Care"},"image":{"@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ameripharma\/"]},{"@type":"Person","@id":"https:\/\/ameripharmaspecialty.com\/#\/schema\/person\/234280933b6e0dcaf47c0c1f40a59759","name":"Dr. Robert Hakim, Doctor en Farmacia","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ce5316336fea18759f2cf91c9f6269796c7cb578013d4d04c78cb734056a87d?s=96&d=mm&r=g","caption":"Dr. Robert Hakim, PharmD"},"description":"El Dr. Robert Chad Hakim, PharmD, naci\u00f3 y creci\u00f3 en Northridge, California. Obtuvo su t\u00edtulo en farmacia en la Facultad de Farmacia de la Universidad de Wisconsin-Madison. Lo m\u00e1s gratificante de su trabajo es tomar la iniciativa para impulsar programas cl\u00ednicos que maximicen el impacto en la atenci\u00f3n al paciente. Cuenta con una certificaci\u00f3n del consejo en cuidados cr\u00edticos (BCCCP) y sus \u00e1reas de especializaci\u00f3n son cuidados cr\u00edticos, informaci\u00f3n sobre medicamentos, medicina general y cardiolog\u00eda. En su tiempo libre, disfruta viajando.\u00a0","url":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"}]}},"uagb_featured_image_src":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-300x200.jpg",300,200,true],"medium_large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-768x512.jpg",768,512,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false]},"uagb_author_info":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"},"uagb_comment_info":0,"uagb_excerpt":"Acquired red cell aplasia or acquired pure red cell aplasia is a sub-type of pure red cell aplasia (PRCA), a rare blood disorder in which the bone marrow does not produce enough red blood cells (RBCs).","rttpg_featured_image_url":{"full":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"landscape":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"portraits":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"thumbnail":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-150x150.jpg",150,150,true],"medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-300x200.jpg",300,200,true],"large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-1024x682.jpg",1024,682,true],"1536x1536":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"2048x2048":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false],"trp-custom-language-flag":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",18,12,false],"block-image-html-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-600x400.jpg",600,400,true],"ct-gallery":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-330x220.jpg",330,220,true],"ct-section-header":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-1146x380.jpg",1146,380,true],"ct-thumb":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-86x57.jpg",86,57,true],"ct-thumb-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-167x111.jpg",167,111,true],"ct-small":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-280x187.jpg",280,187,true],"ct-medium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-370x247.jpg",370,247,true],"ct-xmedium":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm-960x640.jpg",960,640,true],"ct-large":["https:\/\/ameripharmaspecialty.com\/wp-content\/uploads\/2025\/01\/ivig-arm.jpg",1280,853,false]},"rttpg_author":{"display_name":"Dr. Robert Hakim, PharmD","author_link":"https:\/\/ameripharmaspecialty.com\/es\/author\/robert-hakim\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/ameripharmaspecialty.com\/es\/category\/ivig\/\" rel=\"category tag\">IVIG<\/a>","rttpg_excerpt":"Acquired red cell aplasia or acquired pure red cell aplasia is a sub-type of pure red cell aplasia (PRCA), a rare blood disorder in which the bone marrow does not produce enough red blood cells (RBCs).","_links":{"self":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27090","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/users\/26"}],"replies":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/comments?post=27090"}],"version-history":[{"count":0,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/posts\/27090\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media\/27091"}],"wp:attachment":[{"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/media?parent=27090"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/categories?post=27090"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ameripharmaspecialty.com\/es\/wp-json\/wp\/v2\/tags?post=27090"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}